Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.11
-$0.24(-1.26%)
At close: 4:00 PM EDT
$19.11
-$0.24(-1.26%)
Day’s Range― - ―
52-Week Range$1.33 - $24.28
Previous Close$19.1
Volume3.53M
Average Volume (3M)5.45M
Market Cap
$6.36B
Enterprise Value$5.48K
Total Cash (Recent Filing)$268.74M
Total Debt (Recent Filing)$44.71M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding347,127,400
10 Day Avg. Volume5,434,020
30 Day Avg. Volume5,453,502
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.57Price Target Upside18.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising ERAS-0015 Clinical DataRobust early monotherapy activity (57% ORR at the recommended expansion dose) with favorable tolerability materially de-risks the lead oncology asset. Durable clinical signals support accelerated registration-enabling plans and strengthen the company’s long-term commercial opportunity in high-value RAS-mutant indications.
Large Equity Raise Strengthens FundingA sizable primary equity raise meaningfully extends runway to advance clinical programs and enables execution of planned Phase 3/registration-enabling studies. This reduces immediate financing pressure and allows management to prioritize development cadence and evidence generation without near-term capital constraints.
Manageable Leverage And Sizable Equity BaseRelatively low leverage and a meaningful equity capital base provide financial flexibility uncommon in early-stage biotech. Manageable debt levels reduce bankruptcy risk and, alongside the equity base, support the company’s ability to fund R&D and absorb operational losses while pursuing medium-term clinical milestones.
Bears Say
No Meaningful RevenueThe absence of commercial revenue means the company cannot self-fund operations and remains fully dependent on external capital until product approvals. This structural lack of earnings power prolongs reliance on markets and partners, raising sustainability risk over the medium term.
High And Accelerating Cash BurnConsistently large negative operating and free cash flows, with a recent sharp deterioration, create ongoing funding needs. Even with recent capital raises, accelerating cash burn increases the probability of future dilution or financing complexity and constrains strategic optionality over the next several quarters.
Legal Uncertainty Around ERAS-0015Allegations or legal disputes tied to the lead asset can delay development, complicate regulatory filings, deter partners, and raise defense costs. This introduces a material structural risk to the core program that underpins the company’s long-term value-creation plan and could impede commercialization timelines.
Erasca News
ERAS FAQ
What was Erasca, Inc.’s price range in the past 12 months?
Erasca, Inc. lowest stock price was $1.33 and its highest was $24.28 in the past 12 months.
What is Erasca, Inc.’s market cap?
Erasca, Inc.’s market cap is $6.36B.
When is Erasca, Inc.’s upcoming earnings report date?
Erasca, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.
How were Erasca, Inc.’s earnings last quarter?
Erasca, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.029.
Is Erasca, Inc. overvalued?
According to Wall Street analysts Erasca, Inc.’s price is currently Undervalued.
Does Erasca, Inc. pay dividends?
Erasca, Inc. does not currently pay dividends.
What is Erasca, Inc.’s EPS estimate?
Erasca, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Erasca, Inc. have?
Erasca, Inc. has 347,127,400 shares outstanding.
What happened to Erasca, Inc.’s price movement after its last earnings report?
Erasca, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 0.766%.
Which hedge fund is a major shareholder of Erasca, Inc.?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.57 (18.11% Upside)
$22.57 (18.11% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 965.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1017.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Company Description
Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$22.57
▲(18.11% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
9.72% Insiders
11.43% Mutual Funds
2.51% Other Institutional Investors
65.34% Public Companies and
Individual Investors